Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome
| Author | S Abdi | en |
| Author | M Momtahen | en |
| Author | F Javadzadeh | en |
| Author | BF Farsad | en |
| Author | AS Kazzazi | en |
| Author | , Sharifian | en |
| Author | S Momtahen | en |
| Issued Date | 2009-06-30 | en |
| Abstract | Background: Recent trials of platelet glycoprotein IIb/IIIa receptor inhibitors have improved our understanding to best use these powerful antiplatelet drugs in acute coronary syndrome. We tested the hypothesis that inhibition of GPIIb/IIIa platelet receptor with Eptifibatide is effective as an empiric therapy in patients with acute coronary syndrome who do not necessarily undergo immediate revascularization.Methods: Since Feb 2006 one hundred and ninety-six patients who had presented with non ST-elevation acute coronary syndrome (NSTE-ACS) were randomly assigned to receive Eptifibatide in addition to standard therapy, for up to 72 hours or routine standard therapy. The primary end point was composite of death and non-fatal myocardial infarction (MI) or urgent target vessel revascularization (TVR) in 30 days.Results: The incidence of composite end point of death, non fatal MI and urgent TVR was significantly lower in Eptifibatide group than standard group (16% vs. 0% - P value | en |
| DOI | https://doi.org/ | en |
| URI | https://brieflands.com/journals/ircrj/articles/68402 | en |
| Keyword | GP IIb/IIIa Receptor Inhibitor | en |
| Keyword | Eptifibatide | en |
| Keyword | Acute Coronary Syndrome | en |
| Publisher | Brieflands | en |
| Title | Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- icrj-03-86.PDF
- Size:
- 355.45 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF